Related Experiment Videos
Imatinib mesylate: A designer drug.
1Department of Hematology, All India Institute of Medical Sciences, New Delhi-29, India.
The Journal of the Association of Physicians of India
|June 28, 2006
Summary
Imatinib, a targeted cancer therapy, is a leading treatment for chronic myelogenous leukemia and other conditions. Its success drives research into new molecularly targeted drugs.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Molecularly targeted therapy represents a significant advancement in cancer treatment strategies.
- Imatinib, a tyrosine kinase inhibitor, has revolutionized the management of chronic myelogenous leukemia (CML).
Purpose of the Study:
- To provide a comprehensive review of imatinib mesylate.
- To detail its development, biological mechanisms, clinical utility, and limitations.
Main Methods:
- Literature review of imatinib's development and clinical applications.
- Analysis of preclinical and clinical data on imatinib efficacy.
- Synthesis of information on imatinib's pharmacology and limitations.
Main Results:
- Imatinib is the first-line treatment for chronic phase CML.
- It shows efficacy in gastro-intestinal stromal tumors, eosinophilic disorders, and Philadelphia chromosome-positive ALL.
- Its success has spurred further development of targeted cancer therapies.
Conclusions:
- Imatinib mesylate is a cornerstone of molecularly targeted cancer therapy.
- Ongoing research continues to explore and refine targeted drug development.
- Understanding imatinib's profile is crucial for its optimal clinical application.